652 filings
Page 20 of 33
424B3
cqwiqtnt0x3
18 Oct 10
Prospectus supplement
12:00am
8-K
m2pu0p iq3
18 Oct 10
OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
12:00am
8-K
dv0bi31wttg k9xf
15 Oct 10
Other Events
12:00am
8-K
85n g3ngg
30 Sep 10
Teva and Oncogenex Announce Initiation of Second Phase 3 Trial of Custirsen In Men with Metastatic Prostate Cancer
12:00am
8-K
5zs7d2s ff
27 Sep 10
OncoGenex Pharmaceuticals Announces Initiation of a Phase 2 Trial Evaluating OGX-427 Treatment in Men with Advanced Prostate Cancer
12:00am
S-8
xsb ispkip9gmr2
13 Aug 10
Registration of securities for employees
12:00am
8-K
0e28 v0aq
10 Aug 10
OncoGenex Adds David V. Smith to the Board of Directors
12:00am
8-K/A
zlzo50c
5 Aug 10
Submission of Matters to a Vote of Security Holders
12:00am
8-K
77t5bw97y9h9
5 Aug 10
Results of Operations and Financial Condition
12:00am
8-K
g62i3z63yur
23 Jun 10
OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
12:00am
8-K
xji3z3il4q40
14 Jun 10
Departure of Directors or Certain Officers
12:00am
8-K
lcj7t0ao8mf1fl
7 Jun 10
OncoGenex Pharmaceuticals Announces Final Results from Phase 1 Trial Evaluating OGX-427 as a Treatment for Solid Tumors
12:00am
CT ORDER
j1c708ps6rf
11 May 10
Confidential treatment order
12:00am
8-K
c0cbo7
6 May 10
Results of Operations and Financial Condition
12:00am
8-K
391xoyz4ykcvgsnl
25 Mar 10
Data from OncoGenex Pharmaceuticals’ Product Candidate OGX-427 to be Presented at the American Society of Clinical Oncology Annual Meeting
12:00am